0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Zomedica Pharmaceuticals Corp

Healthcare US ZOM

0.1301USD
0.0001(0.08%)

Last update at 2024-04-25T20:10:00Z

Day Range

0.130.13
LowHigh

52 Week Range

0.150.34
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -19.38100M -20.71622M -16.91178M -19.78405M -16.64769M
Minority interest - - - - 0.00000M
Net income -17.01500M -18.38317M -16.92112M -19.82213M -16.64769M
Selling general administrative 33.00M 22.75M 7.93M 8.18M 5.83M
Selling and marketing expenses - - 0.26M 0.47M 0.23M
Gross profit 13.65M 3.05M - - 0.00000M
Reconciled depreciation 4.04M 1.14M 0.53M 0.79M 0.21M
Ebit -21.92300M -21.37400M -16.76498M -19.78433M -16.51081M
Ebitda -15.18700M -19.82510M -16.19350M -18.97698M -16.30504M
Depreciation and amortization 6.74M 1.55M 0.57M 0.81M 0.21M
Non operating income net other -0.15800M -0.76045M -0.08698M -0.00113M -0.06844M
Operating income -21.92300M -21.37400M -16.76498M -19.78433M -16.57925M
Other operating expenses 40.85M 25.51M 16.76M 19.78M 16.58M
Interest expense 0.00100M 0.00605M 0.00073M 0.02M 0.00000M
Tax provision -2.36600M -2.33305M 0.00000M 0.00000M 0.00000M
Interest income 2.55M 0.32M 0.03M 0.02M 0.00094M
Net interest income 2.70M 0.35M 0.03M -0.01834M -
Extraordinary items - - - - 0.00000M
Non recurring - 0.00600M - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -2.36600M -2.33305M 0.00933M 0.04M 0.14M
Total revenue 18.93M 4.13M 0.00000M 0.00000M 0.00000M
Total operating expenses 35.58M 24.43M 16.76M 19.78M 16.58M
Cost of revenue 5.28M 1.08M - - 0.00000M
Total other income expense net 2.54M 0.66M -0.14681M 0.00027M -0.06844M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -17.01500M -18.38317M -16.91178M -19.78405M -16.64769M
Net income applicable to common shares -17.01500M -18.38317M -16.91178M -19.78405M -16.64769M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 279.61M 280.40M 66.14M 4.18M 6.03M
Intangible assets 41.80M 33.52M 0.38M 0.54M 0.01M
Earning assets - - - - -
Other current assets 3.80M 1.84M 3.05M 1.23M 1.87M
Total liab 12.22M 9.51M 15.08M 2.09M 2.38M
Total stockholder equity 267.39M 270.89M 51.07M 2.10M 3.66M
Deferred long term liab 1.25M - - - 0.00000M
Other current liab 0.27M 0.50M 1.25M 2.09M 2.38M
Common stock 380.97M 380.96M 104.78M 38.57M 30.41M
Capital stock 380.97M 380.96M 104.78M 50.53M 30.41M
Retained earnings -136.40400M -119.39140M -68.96962M -52.05784M -32.27379M
Other liab 3.31M 4.21M - - 0.00000M
Good will 63.98M 43.29M - - 0.00000M
Other assets 0.45M 0.36M 1.00M 0.00000M 1.44M
Cash 27.40M 194.95M 61.99M 0.51M 1.94M
Cash and equivalents 27.40M 194.95M 61.99M 0.51M 1.94M
Total current liabilities 7.81M 4.34M 2.03M 2.09M 2.38M
Current deferred revenue 0.21M 0.20M - - -
Net debt -25.66100M -193.57332M -60.12356M -0.51059M -1.94026M
Short term debt 0.64M 0.41M 0.78M 0.00000M 0.00000M
Short long term debt - - 0.53M - 0.00000M
Short long term debt total 1.74M 1.38M 1.87M - -
Other stockholder equity 23.67M 9.31M 15.25M 3.63M 5.79M
Property plant equipment 6.81M 2.53M 0.58M 1.83M 0.72M
Total current assets 123.50M 200.41M 62.87M 1.81M 3.86M
Long term investments 40.71M - - - 0.00000M
Net tangible assets 161.61M 194.08M 50.69M -10.40933M 3.64M
Short term investments 87.69M - - 1.03M 1.26M
Net receivables 1.86M 0.77M 0.15M 0.07M 0.05M
Long term debt - - - - 0.00000M
Inventory 2.75M 2.85M - - 0.00000M
Accounts payable 6.70M 3.23M 0.00125M 2.09M 2.38M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -0.84300M 0.00167M - -0.54665M -0.27041M
Additional paid in capital - - - - 0.00000M
Common stock total equity 380.97M 380.96M 0.00046M 38.57M 30.41M
Preferred stock total equity - - 11.96M 11.96M 0.00000M
Retained earnings total equity -136.40400M -119.39140M -68.96962M -52.05784M -32.27379M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - -
Non currrent assets other 0.45M 0.66M 1.00M 1.83M 1.44M
Deferred long term asset charges - - - - -
Non current assets total 156.11M 79.99M 3.28M 2.38M 2.17M
Capital lease obligations 1.74M 1.38M 1.34M - -
Long term debt total 1.10M 0.96M 1.09M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -128.78600M -71.92537M 1.01M -0.68693M -0.61900M
Change to liabilities 2.69M -1.11009M -0.83890M -0.28899M 1.55M
Total cashflows from investing activities -155.88000M -71.92537M 1.01M -0.68693M -0.61900M
Net borrowings - - 0.53M 0.53M 0.53M
Total cash from financing activities 0.00800M 219.16M 76.71M 14.89M 10.26M
Change to operating activities -2.50800M -0.14037M -0.79850M 0.33M -1.95634M
Net income -17.01500M -18.38317M -16.91178M -19.78405M -16.64769M
Change in cash -167.55300M 132.96M 61.48M -1.42968M -1.50788M
Begin period cash flow 194.95M 61.99M 0.51M 1.94M 3.45M
End period cash flow 27.40M 194.95M 61.99M 0.51M 1.94M
Total cash from operating activities -11.67000M -14.27516M -16.23936M -15.63406M -11.14753M
Issuance of capital stock 0.00000M 199.53M 56.50M 15.00M -
Depreciation 4.04M 1.14M 0.53M 0.79M 0.21M
Other cashflows from investing activities -26.30700M -71.77824M 1.02M -0.53142M 0.00900M
Dividends paid - - - - 0.00000M
Change to inventory -4.00800M -2.77448M -2.77448M -2.77448M -2.77448M
Change to account receivables -0.28300M -0.04708M -0.07859M -0.01396M -0.02539M
Sale purchase of stock 0.00800M 231.66M 75.73M 14.89M 10.26M
Other cashflows from financing activities 0.00800M 19.63M 20.22M 11.89M 10.26M
Change to netincome 7.89M 6.84M 1.80M 3.33M 5.73M
Capital expenditures 1.03M 0.53M 0.02M 0.69M 0.63M
Change receivables -0.61700M 0.21M -0.07859M -0.01396M -0.02539M
Cash flows other operating -3.75400M 2.63M -0.69695M 0.84M -1.95634M
Exchange rate changes - 0.00166M - - -
Cash and cash equivalents changes -167.54200M 132.96M 61.48M -1.42968M -1.50788M
Change in working capital -5.70300M -3.87579M -1.71598M 0.03M -0.43395M
Stock based compensation 7.89M 7.09M 1.66M 2.54M 0.00729M
Other non cash items 1.47M 0.04M 0.02M 0.79M 5.65M
Free cash flow -12.69600M -14.80133M -16.25616M -16.32100M -11.77553M

Fundamentals

  • Previous Close 0.13
  • Market Cap210.69M
  • Volume1333093
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-19.67900M
  • Revenue TTM24.01M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 13.65M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZOM
Zomedica Pharmaceuticals Corp		 0.0001 0.08% 0.13 - - 8.42 0.77 4.07 -8.1785
ZTS
Zoetis Inc		 2.48 1.64% 153.36 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.37 1.14% 32.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 6.97 4.40% 165.33 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16 1.21% 13.07 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Zomedica Pharmaceuticals Corp

100 Phoenix Drive, Ann Arbor, MI, United States, 48108

Key Executives

Name Title Year Born
Mr. Larry C. Heaton II Pres & CEO 1957
Ms. Ann Marie Cotter CPA Chief Financial Officer 1969
Mr. Adrian Lock VP, GM & Head of Sales 1961
Mr. Anthony K. Blair Chief Operating Officer 1961
Mr. Evan St. Peter VP of Technology Innovation NA
Ms. Karen DeHaan-Fullerton J.D. Gen. Counsel, Chief Counsel & Corp. Sec. 1968
Ms. Nicole Westfall VP of Marketing NA
Ms. Kristin Domanski VP of HR NA
Dr. Stephanie Laine Morley D.V.M., DVM Consultant 1975
Dr. William Carpenter MacArthur Consultant 1963

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).